Method of treating tumors

Abstract

A method of treating tumors, such as prostate tumors, breast tumors, non-Hodgkin's lymphoma, and the like, includes the sequential steps of administering to the patient at least one dose of an antiangiogenic cyclo-arginine-glycine-aspartic acid-containing pentapeptide (cRGD pentapeptide); administering to the patient an anti-tumor effective amount of a radioimmunotherapeutic agent (RIT); and then administering to the patient at least one additional dose of cRGD pentapeptide. The cRGD pentapeptide is preferably cyclo-(Arg-Gly-Asp-D-Phe-[N-Me]-Val), and the RIT is preferably a radionuclide-labeled chelating agent-ligand complex in which chelating agent is chemically bonded to a tumor-targeting molecule, such as a monoclonal antibody.

1 . A kit comprising a first container including at least one unit dose of a RIT and one or more additional containers including a total of at least two unit doses of cRGD pentapeptide.  
     
     
         2 . A kit according to  claim 1  wherein the containers each include a label describing the contents of the container and any other pertinent information required by government regulations relating to pharmaceuticals and radioactive substances.  
     
     
         3 . A kit according to  claim 1  further including printed instructions for use of the container contents for treatment of tumors.  
     
     
         4 . The kit according to  claim 1  wherein the cRGD pentapeptide is cyclo-(Arg-Gly-Asp-D-Phe-[N-Me]-Val).  
     
     
         5 . The kit according to  claim 1  wherein the RIT is a radionuclide-labeled chelating agent-ligand complex in which chelating agent is chemically bonded to a tumor-targeting molecule.  
     
     
         6 . The kit according to  claim 5  wherein the tumor-targeting molecule is a monoclonal antibody.  
     
     
         7 . The kit according to  claim 6  wherein the monoclonal antibody is an anti-tumor monoclonal antibody.  
     
     
         8 . The kit according to  claim 7  wherein the anti-tumor monoclonal antibody is an anti-MUC-1 monoclonal antibody.  
     
     
         9 . The kit according to  claim 7  wherein the anti-tumor monoclonal antibody is a chimeric L6 monoclonal antibody.  
     
     
         10 . The kit according to  claim 7  wherein the anti-tumor monoclonal antibody is M170 anti-MUC-1 monoclonal antibody.  
     
     
         11 . The kit according to  claim 5  wherein the chelating agent is a polyazamacrocyclic group or a polyoxamacrocyclic group.  
     
     
         12 . The kit according to  claim 11  wherein said chelating group is derived from a member of the group consisting of: 
 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid;    1,4,7,10-tetraazacyclotridecane-N,N′,N″,N′″-tetraacetic acid;    1,4,8,11-tetraazacyclotetradecane-N,N′,N″,N′″-tetraacetic acid; and    1,5,9,13-tetraazacyclohexadecane-N,N′,N″,N′″-tetraacetic acid.    
     
     
         13 . The kit according to  claim 5  wherein the radionuclide is  90 Y.  
     
     
         14 . The kit according to  claim 5  wherein the chelating agent is N-substituted 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid; wherein the N-substituent is —CH 2 C(═O)-(Gly) 3 -L-(p-isothiocyanato)-Phe-amide and the radionuclide is  90 Y.